NCT06788652 A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
| NCT ID | NCT06788652 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
| Condition | Mantle Cell Lymphoma (MCL) |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-02-04 |
| Primary Completion | 2044-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-02-04 with a primary completion date of 2044-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).
Eligibility Criteria
Inclusion Criteria: • Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) used for the treatment of Mantle Cell Lymphoma (MCL) according to the FDA-approved indication and dose range (ie, per the US Prescribing Information) and with a product meeting the specifications for commercial release approved in the USA Exclusion Criteria: * Participants known to be participating in investigational studies at the time of liso-cel infusion. * Participants treated with non-conforming CAR T-cell product.
Contact & Investigator
Bristol-Myers Squibb
STUDY DIRECTOR
Bristol-Myers Squibb
Frequently Asked Questions
Who can join the NCT06788652 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Mantle Cell Lymphoma (MCL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06788652 currently recruiting?
Yes, NCT06788652 is actively recruiting participants. Contact the research team at Clinical.Trials@bms.com for enrollment information.
Where is the NCT06788652 trial being conducted?
This trial is being conducted at Milwaukee, United States.
Who is sponsoring the NCT06788652 clinical trial?
NCT06788652 is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The principal investigator is Bristol-Myers Squibb at Bristol-Myers Squibb. The trial plans to enroll 300 participants.